Designing of thermosensitive liposomes from natural lipids for multimodality cancer therapy

Abstract

Thermosensitive liposomes prepared from synthetic lipids such as dipalmitoyl phosphatidylcholine, distearoyl phosphatidyl choline and cholesterol (Ch) have been tried for local drug release in response to hyperthermia for achieving tumour drug targeting. Herein we report a novel method of preparation of temperature-sensitive liposomes using natural lipids egg phosphatidylcholine (PC):Ch (7:1 molar ratio) and ethanol 6% (v/v) having a transition temperature of 43 degrees C, temperature attainable by local hyperthermic treatment of tumours. The anticancer drug decarbazine [5-(3,3'-dimethyl-1-triazino) imidazole-4-carboxamide] was entrapped in these liposomes. The in vivo efficacy of temperature-sensitive unilamellar vesicles encapsulated decarbazine in combination with hyperthermia was determined in murine fibrosarcomas. These PC:Ch liposomes are biodegradable, non-toxic and more cost effective in comparison with liposomes prepared from synthetic lipids for use in multimodality cancer therapy.

Nanoscale Drug Delivery and Hyperthermia: The Materials Design and Preclinical and Clinical Testing of Low Temperature-Sensitive Liposomes Used in Combination with Mild Hyperthermia in the Treatment of Local Cancer

“…Other drugs including taxol [146], melphalan [147, 148], methotrexate [141, 149], plumbagin [150], dacarbazine [151], mitomycin C [152] and tumor necrosis factor [153], have also been encapsulated (see review by Kong and Dewhirst [154]). Currently only the LTSL-doxorubicin is in clinical trials, but an optimized formulation for cisplatin and other drugs may be possible for the near future.…”

Evolving lipid-based delivery systems in the management of neoplastic disease

“…After intravenous administration of such liposomes, a localized external source of hyperthermia leads to improved local drug delivery [98,99].…”

Hyperthermia and nanotechnology–A note from the Editor-in-chief

“…Since then several other papers have been published in the Journal with subjects ranging from in vitro studies of liposome cell interactions and imaging to clinical trials [2][3][4][5][6][7][8][9][10][11][12][13][14]. In this issue, Chen et al report on the influence of differences in vascular permeability on the efficacy of a novel doxorubicin-containing thermally sensitive liposome.…”